<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996411</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00009081</org_study_id>
    <nct_id>NCT00996411</nct_id>
  </id_info>
  <brief_title>Human Psychopharmacology of Salvinorin A</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      This study is characterizing the subject-rated and behavioral effects of salvinorin A in&#xD;
      healthy volunteers. The investigators hypothesize the salvinorin A will have&#xD;
      hallucinogen-like effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hallucinogen Rating Scale</measure>
    <time_frame>Approximately 1 hour after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Salvinorin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvinorin A</intervention_name>
    <description>This is an initial dose ranging study</description>
    <arm_group_label>Salvinorin A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
          -  Have a high school level of education&#xD;
&#xD;
          -  Have a self-reported interest in spirituality and altered states of consciousness&#xD;
&#xD;
          -  Have used hallucinogens (e.g., LSD, psilocybin mushrooms, Salvia divinorum) including&#xD;
             having used Salvia divinorum or salvinorin A by the inhalation route (i.e., volunteers&#xD;
             without histories of Salvia divinorum or salvinorin A use by the inhalation route will&#xD;
             be excluded)&#xD;
&#xD;
          -  Be 21 to 65 years old&#xD;
&#xD;
          -  Agree to consume approximately the same amount of caffeine-containing beverage (e.g.,&#xD;
             coffee, tea) that he/she consumes on a usual morning, before arriving at the research&#xD;
             unit on the mornings of drug session days. If the volunteer does not routinely consume&#xD;
             caffeinated beverages, he or she must agree not to do so on session days.&#xD;
&#xD;
          -  Agree to refrain from using any psychoactive drugs, including alcoholic beverages,&#xD;
             within 24 hours of each drug administration. As described elsewhere, exceptions&#xD;
             include daily use of caffeine.&#xD;
&#xD;
          -  Be healthy as determined by screening for medical problems via a personal interview, a&#xD;
             medical questionnaire, a physical examination, an electrocarroutine medical blood and&#xD;
             urinalysis laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Medical Exclusion Criteria&#xD;
&#xD;
          -  Cardiovascular conditions: uncontrolled hypertension, angina, a clinically significant&#xD;
             ECG abnormality (e.g. atrial fibrillation), TIA in the last 6 months stroke,&#xD;
             peripheral or pulmonary vascular disease&#xD;
&#xD;
          -  Epilepsy with history of seizures&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Females who are pregnant (positive pregnancy test) or nursing, or are not practicing&#xD;
             an effective means of birth control&#xD;
&#xD;
          -  Currently taking psychoactive prescription medication on a regular basis&#xD;
&#xD;
          -  More than 20% outside the upper or lower range of ideal body weight according to&#xD;
             Metropolitan Life height and weight table&#xD;
&#xD;
        Psychiatric Exclusion Criteria&#xD;
&#xD;
          -  Current or past history of meeting DSM-IV criteria for Schizophrenia, Psychotic&#xD;
             Disorder (unless substance-induced or due to a medical condition), or Bipolar I or II&#xD;
             Disorder.&#xD;
&#xD;
          -  Current severe Obsessive-Compulsive Disorder, Dysthymic Disorder, or Panic Disorder.&#xD;
&#xD;
          -  Current or past history within the last 5 years of meeting DSM-IV criteria for alcohol&#xD;
             or drug dependence (excluding caffeine and nicotine) or severe major depression.&#xD;
&#xD;
          -  Have a first or second degree relative with schizophrenia, psychotic disorder (unless&#xD;
             substance induced or due to a medical condition), or bipolar I or II disorder.&#xD;
&#xD;
          -  Currently meets DSM-IV criteria for Dissociative Disorder, Anorexia Nervosa, Bulimia&#xD;
             Nervosa, or other psychiatric conditions judged to be incompatible with establishment&#xD;
             of rapport or safe exposure to salvinorin A.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Griffiths, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew W Johnson, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit, Johnson Hopkins Univ. School of Med.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Roland Griffiths</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry,</investigator_title>
  </responsible_party>
  <keyword>Healthy volunteers are being studied to evaluate the subject-rated, behavioral, and abuse liability effects of salvinorin A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salvinorin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

